Anticoagulants Market Value to Expand $43,427 Million by 2025, says AMR
Anticoagulant drugs (also known as blood thinners) are chemical substances that prevent or reduce coagulation of blood and prolong the blood clotting time. These drugs are majorly used for high risk of blood clots in various medical conditions, such as atrial fibrillation, deep vein thrombosis, myocardial infarction, pulmonary embolism, stroke, and others. The global anticoagulants industry is anticipated to show significant growth during the forecast period, owing to increasing prevalence of venous thromboembolism (VTE) and cardiovascular disorders, growing adoption of novel oral anticoagulants (NOACs), and rising awareness of NOACs in the developing region.
Download Sample Report @ https://www.alliedmarketresearch.com/request-sample/1673?utm_source=opr_sank
On the basis of drug class, the anticoagulants market is segmented as NOACs, heparin & LMWH, vitamin K antagonist, and others. At present, the NOACs segment is a major revenue-generating segment and is anticipated to show dominance during the forecast period, owing to growing awareness of NOACs and rising use of NOACs over the warfarin. However, higher price of NOACs hinders the market growth. As per the route of administration, the anticoagulants market is segmented as oral anticoagulant and injectable anticoagulant. At present, the oral anticoagulant segment is a major revenue-generating segment and is anticipated to show dominance during the forecast period, owing to growing adoption of NOACs and rising availability of lower cost warfarin.
The application market is categorized as atrial fibrillation & heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and others. Presently, the atrial fibrillation & heart attack segment is a major revenue contributor and is anticipated to show dominance throughout the forecast period, owing to large target population and increase in use of anticoagulants to treat these conditions. However, the DVT segment is expected to show the fastest market growth, attributed to the increase in prevalence of DVT and technological advancement in diagnosis of DVT.
North America accounted approximately one-half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. This was attributed to the higher demand for novel therapeutics, strong presence of key players, early diagnosis, developed healthcare infrastructure, presence of trained medical professionals, and larger target population. However, the Asia-Pacific region is expected to experience the highest growth rate during the forecast period, majorly owing to improving healthcare infrastructure with developing economies, rising diagnosis rate, enhancing health awareness, and increasing prevalence of cardiovascular disease and VTE.
Key Findings of the Anticoagulants Market:
• As per the drug class, the NOACs segment is expected to show the fastest market growth and grow at a CAGR of 8.0% from 2018 to 2025.
• On the basis of the route of administration, the oral anticoagulant segment held more than half of the global market share in 2017 and is expected to remain dominant throughout the forecast period.
• By application, the deep vein thrombosis (DVT) segment is expected to exhibit the fastest growth at a CAGR of 8.4% from 2018 to 2025.
• Region-wise, the Asia-Pacific region is expected to experience growth at the highest rate, registering a CAGR of 9.2% during the forecast period.
Flat 20% Discount on All License Type .. https://www.alliedmarketresearch.com/checkout/946431?utm_source=opr_sank
*Offer Valid Till 20th April 2019
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client's insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.
5933 NE Win Sivers Drive
#205, Portland, OR 97220
Toll Free: +1-800-792-5285
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
This release was published on openPR.
Permanent link to this press release:
You can edit or delete your press release Anticoagulants Market Value to Expand $43,427 Million by 2025, says AMR here
News-ID: 1683383 • Views: 318
More Releases from Allied Market Research
North America Geogrid Market 2020 Segmentation, Demand, Growth, Trend, Opportuni …
According to the report published by Allied Market Research, the North America geogrid market generated $282.0 million in 2019, and is estimated to reach $408.25 million by 2027, registering a CAGR of 7.0% from 2020 to 2027. The report offers an extensive analysis of changing market dynamics, key winning strategies, business performance, major segments, and competitive scenarios. Surge in infrastructure development activities across the U.S. and Mexico and superior physical properties
Intravenous Immunoglobulin (IVIG) Market 2020 In-Depth Analysis of Industry Shar …
Global intravenous immunoglobulin market accounted for $8,995 million in 2017, and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025. Immunoglobulin (Ig) is a plasma-derived product, which is obtained from the serum of healthy donors. The isolated plasma product is clinically treated and purified to Ig, which can be further used in the treatment of patients with antibody deficiency. Intravenous immunoglobulin (IVIG) finds
Asthma and COPD Drugs Market Is Expected to Witness a Steady Growth by 2026
"Asthma and COPD Drugs Market by Disease and Medication Class - Global Opportunity Analysis and Industry Forecasts, 2014-2022", projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America
Synthetic Biology Market in Global Industry by Top Companies, Type and Applicati …
Global Synthetic biology market is forecast to reach $38.7 billion by 2020, at a CAGR of 44.2% during the forecast period (2014 - 2020). Europe occupies largest share in the global market and would hold-on to its position throughout 2020. However, Asia Pacific is the fastest growing market with a CAGR of 46.4% from 2014 - 2020. Read Full Report @ https://www.alliedmarketresearch.com/synthetic-biology-market Synthetic biology is at a nascent stage and has recently
More Releases for NOACs
US Anticoagulation Therapy Market|Key players in the US anticoagulation therapy …
The report "US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based) - Forecast to 2022", The US anticoagulation therapy market has witnessed a healthy growth rate during the last decade and is expected to grow at a CAGR of 8.5% between 2017 and 2022 to reach USD 27.83 Billion by 2022.
Anticoagulants Market to extend at $43,427 Million, with a growing CAGR by 2025
The Anticoagulants Market was valued at $24,265 million in 2017, and is predicted to grow at $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025. The global anticoagulants industry is anticipated to show significant growth during the forecast period, owing to increasing prevalence of venous thromboembolism (VTE) and cardiovascular disorders, growing adoption of novel oral anticoagulants (NOACs), and rising awareness of NOACs in the developing region.
Anticoagulants Market Insights 2018-2025: Sanofi, Bristol-Myers Squibb, Bayer, J …
The global anticoagulants market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025. The key players profiled in this report of anticoagulants market include Aspen Holdings, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc., Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Pfizer, Inc., Portola Pharmaceuticals, Inc., and Sanofi S.A. Anticoagulants
Anticoagulants Market Key Players : Aspen Holdings, Bayer AG, Boehringer Ingelhe …
The global anticoagulants market was valued at $24,265 million in 2017, and is expected to reach $43,427 million by 2025, growing at a CAGR of 7.5% from 2018 to 2025. Anticoagulant drugs (also known as blood thinners) are chemical substances that prevent or reduce coagulation of blood and prolong the blood clotting time. These drugs are majorly used for high risk of blood clots in various medical conditions, such as atrial
US Anticoagulation Therapy Market to Reach US$ 27 Billion By 2022
Florida, January 16, 2018: Market Research Engine has published a new report titled as “US Anticoagulation Therapy Market By Product Type Analysis (US Anticoagulation Therapy (Products) Market, US Anticoagulation Therapy (Products) Market For PT/INR Testing Devices, US Anticoagulation Therapy Market For Clinics) and by Regional Analysis - Global Forecast by 2016 - 2022”. The growth within the anticoagulation medication market is primarily driven by the rising incidence of blood vessel occlusion,
NOACs Pricing, Reimbursement, and Access
ReportsWorldwide has announced the addition of a new report title NOACs Pricing, Reimbursement, and Access to its growing collection of premium market research reports. A combination of the high cost of novel oral anticoagulants (NOACs) (relative to highly genericized vitamin K antagonists) and the large patient populations these drugs address, has resulted in this class of compounds being a top priority for European payers. The impact of NOACs on European budgets